New drug duo aims to tackle tough leukemia
Disease control
Recruiting now
This study tests a combination of two drugs, DFP-10917 and venetoclax, in 39 adults with acute myeloid leukemia that has relapsed or not responded to prior treatments. DFP-10917 is given as a continuous 14-day IV infusion, while venetoclax is taken orally for 10-14 days each cycl…
Phase: PHASE1, PHASE2 • Sponsor: Delta-Fly Pharma, Inc. • Aim: Disease control
Last updated Jun 26, 2026 12:50 UTC